Brief: Samsung Bioepis, Teva Expand Strategic Partnership To Advance Up To 6 Potential Biosimilar Candidates
01/10/2026 09:45
BRIEF-Samsung Bioepis, Teva Expand Strategic Partnership To Advance Up To 6 Potential Biosimilar Candidates Oct 1 (Reuters) - Samsung Bioepis:
SAMSUNG BIOEPIS AND TEVA EXPAND STRATEGIC PARTNERSHIP TO ADVANCE UP TO SIX POTENTIAL BIOSIMILAR CANDIDATES
SAMSUNG BIOEPIS - PARTNERSHIP COVERS US, EUROPE, CANADA WITH OPTION TO EXPAND TO OTHER TERRITORIES
SAMSUNG BIOEPIS: CO RESPONSIBLE FOR DEVELOPMENT AND MANUFACTURE; TEVA FOR COMMERCIALIZATION IN US, EUROPE, CANADA
Further company coverage: 0126Z0.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Samsung Epis Holdings
See all newsBrief: Samsung Epis Holdings Says Unit Samsung Bioepis Entered Into Exclusive Supply Agreement Under Brazilian Government Programme For Rare-Disease Treatment
Brief: Samsung Bioepis, Teva Expand Strategic Partnership To Advance Up To 6 Potential Biosimilar Candidates
Brief: Samsung Epis Holdings Co Applies To Korea Food Ministry For Approval Of Pembrolizumab Biosimilar
Brief: Samsung Epis Holdings Co Q2 Operating Profit 86.6 Billion Won, Down 3.6% Y/Y